Purpose of review Hypertension is common in hemodialysis patients and contributes to this population's high risk for cardiovascular morbidity and mortality. Patients with intradialytic hypertension, or increases in blood pressure during hemodialysis, have been shown to have the highest risk for these outcomes. The purpose of this review is to describe new findings that shed light on the epidemiology and pathophysiology of intradialytic hypertension and discuss how a better understanding of these mechanisms may lead to improved blood pressure management and outcomes in hemodialysis patients.
INTRODUCTION
End-stage renal disease patients on hemodialysis have nearly a 20% annual mortality rate, with cardiovascular death being the primary cause [1] . The prevalence of hypertension is nearly 90% in these patients, and it is associated with increased cardiovascular morbidity and mortality [2, 3] . However, the linear relationship between increasing SBP and increasing cardiovascular mortality that exists in the general population [4] does not exist in hemodialysis patients. In fact, a U-shaped curve defines the relationship between single hemodialysis-unit blood pressure (BP) measurements and mortality [5] . It is known that home and ambulatory BP measurements from the interdialytic period are better predictors of mortality than individual prehemodialysis or posthemodialysis BP measurements [6] . Interdialytic BP measurements are considered the gold standard for assessing overall BP burden and risk for catastrophic outcomes in hemodialysis patients. Unfortunately, cost and patient nonadherence may limit clinical use of such measurements. Therefore, it is essential to be able to identify patients at the highest risk for adverse clinical outcomes based on clinical data obtained in the hemodialysis unit.
Recent attention has been directed to the significance of BP changes during a hemodialysis treatment. Although most hemodialysis patients exhibit a decrease in BP during hemodialysis, some patients experience an increase in BP, commonly referred to as intradialytic hypertension. When defined as an increase in SBP of at least 10 mmHg from prehemodialysis to posthemodialysis, intradialytic hypertension has been associated with increased morbidity and mortality in prevalent and incident hemodialysis populations [7, 8] . Our laboratory has focused on identifying potential new mechanisms underlying hypertension among patients on maintenance hemodialysis and the association of intradialytic hypertension with adverse outcomes [9] . The purpose of this article is to present our current understanding of the epidemiology and potential mechanisms of intradialytic hypertension and to discuss the relationship between intradialytic hypertension and ambulatory BP.
DEFINITION AND EPIDEMIOLOGY
We define intradialytic hypertension specifically as an increase in SBP from prehemodialysis to posthemodialysis of at least 10 mmHg. Others have defined intradialytic hypertension as an increase in mean arterial pressure of at least 15 mmHg during or at the end of a hemodialysis treatment [10] [11] [12] [13] . Intradialytic BP changes have also been analyzed using regression analysis of all BP measurements during the course of a hemodialysis treatment [14 && ]. However, the definition of a 10 mmHg increase in SBP from prehemodialysis to posthemodialysis is the only definition that has been associated with increased morbidity and mortality in the hemodialysis patients and, thus, has proven clinical relevance [7, 8] .
The reported prevalence of intradialytic hypertension varies depending on the number of hemodialysis treatments in which BP measurements are ascertained. In retrospective analysis of the Crit Line Intradialytic Monitoring Benefit (CLIMB) study, 13.2% of these prevalent hemodialysis patients had average SBP increases of at least 10 mmHg from prehemodialysis to posthemodialysis when assessed over four hemodialysis treatments [7] . Using this same definition, when hemodialysis unit BP measurements were assessed over 2 weeks, another study reported that 12.2% of incident hemodialysis patients had intradialytic hypertension [8] .
We recently found during a 6-month assessment of all prehemodialysis and posthemodialysis BP measurements, taken during the course of routine hemodialysis treatments in another hemodialysis cohort, that intradialytic hypertension occurred in 21.3% of all treatments [15] . In this observational study, almost every patient encountered at least one episode of intradialytic hypertension over 6 months, but it occurred in more than 31% of the treatments in the quartile of patients that encountered it most often.
SUGGESTED MECHANISMS
The proposed causes of intradialytic hypertension have been previously reviewed [16 & 
,17
& ] and are summarized as follows:
(a) extracellular volume overload; (b) endothelial cell dysfunction; (c) activation of the sympathetic nervous system; (d) activation of the renin-angiotensin-aldosterone system; (e) removal of antihypertensive drugs during hemodialysis; (f) electrolyte changes induced by the dialysate composition. 
Endothelial cell dysfunction
Endothelial cell dysfunction entails an imbalance in the release of vasoconstrictors and vasodilators from KEY POINTS Intradialytic hypertension, defined as an increase in SBP from predialysis to postdialysis of at least 10 mmHg, is associated with increased morbidity and mortality in incident and prevalent hemodialysis patients.
Intradialytic hypertension has recently been associated with underlying endothelial cell dysfunction, supporting prior evidence of increases in plasma endothelin-1 during hemodialysis in these patients.
Patients with intradialytic hypertension have higher average ambulatory SBP compared with hemodialysis patients with decreases in blood pressure from predialysis to postdialysis.
The ambulatory SBP in patients with intradialytic hypertension tends to decrease during the initial 24 h of the interdialytic period, deviating from the typical increase observed in most hemodialysis patients.
Beyond the current recommendations for managing hypertension in all hemodialysis patients, which includes achieving dry weight and adding pharmacologic therapy as necessary, there is insufficient evidence for additional recommendations in patients with intradialytic hypertension at this point. the endothelial cells that favors vasoconstriction.
Initial associations between endothelial cell dysfunction and intradialytic hypertension came from case-control studies that showed increases in plasma endothelin-1 (a potent vasoconstrictor) along with decreases in serum nitric oxide (a potent vasodilator) during hemodialysis in patients with intradialytic hypertension [11, 12] . More recently, Inrig et al. [20 && ] have demonstrated that compared with hemodialysis controls, patients with intradialytic hypertension have decreased circulating plasma endothelial progenitor cells measured before hemodialysis and lower flow-mediated vasodilation measured on nonhemodialysis days. These findings indicate a reduced capacity for endothelial cell repair and an inadequate response of the endothelium to shear stress, respectively. Although underlying endothelial cell dysfunction could potentially explain adverse outcomes during follow-up, it remains unclear how the hemodialysis procedure impacts the balance of vasodilators and vasoconstrictors resulting in intradialytic BP increases. Anecdotally, Fourtounas [21 & ] found that intradialytic BP increases were attenuated during treatments with isolated ultrafiltration compared with ordinary hemodialysis treatments. The author suggested that exposure to dialysate was responsible for this 'malignant intradialytic hypertension.' Although differences in prehemodialysis and posthemodialysis plasma calcium or potassium have not been observed [12] in patients with intradialytic hypertension compared with hemodialysis controls, the role of the dialysate sodium concentration remains an area of interest. Previously, nephrologists used dialysate with sodium concentrations that were lower than patients' prehemodialysis serum sodium concentration to facilitate sodium removal via diffusion. This strategy became unnecessary after hemodialysis machines became equipped with directly programmable ultrafiltration to remove larger amounts of sodium in short periods via convection. To avoid decreases in BP that might result from rapid removal of fluid, higher dialysate sodium concentration became more common. However, in situations where the dialysate sodium concentration exceeds a patient's prehemodialysis serum sodium concentration, the sodium gradient presents a risk for a net positive sodium transfer mediated by diffusion. In the case-control study reported by Inrig et al. [20 && ], there was a trend toward lower prehemodialysis serum sodium in patients with intradialytic hypertension compared with controls. Beyond the potential volume-related implications of sodium transfer during hemodialysis, in-vitro evidence suggests that high sodium concentrations may induce endothelial cell 'stiffening' with impaired release of nitric oxide, resulting in unopposed vasoconstriction [22] . Our laboratory is currently investigating the effects of different dialysis prescriptions on intradialytic hypertension in a clinical trial [23 & ].
Volume overload
The earliest reports of intradialytic hypertension came from small uncontrolled studies in patients with echocardiographic abnormalities including left ventricular dilatation. These studies identified volume overload as the responsible mechanism [18, 19] . With initiation of hemodialysis and ultrafiltration, there was a reduction in end-diastolic volume and an increase in cardiac output, which manifest as an increase in BP. However, with more aggressive ultrafiltration, cardiac output and BP decreased concomitantly. In contrast, a case-control study showed that cardiac output decreased from prehemodialysis to posthemodialysis in all patients, but patients with intradialytic hypertension experienced a greater increase in vascular resistance [12] . No study has directly measured extracellular volume in patients with intradialytic hypertension; however, the impact of interdialytic weight gain has been assessed. Interdialytic weight gain is positively correlated with higher prehemodialysis SBP and with greater reductions in BP during hemodialysis [24] . We have furthermore shown that lower interdialytic weight gain and ultrafiltration volume are both associated with increased occurrences of intradialytic hypertension [25] . Recent retrospective analysis from the Dry weight Reduction in hypertensive hemodialysis Patients (DRIP) study showed that slowly reducing estimated dry weight over several weeks lowered interdialytic BP and caused greater reductions in intradialytic BP, although most of these patients already had intradialytic BP decreases prior to this intervention [14 && ]. The findings from these studies highlight the need for more validated assessments of extracellular volume in the context of intradialytic hypertension.
RELATIONSHIP TO AMBULATORY BLOOD PRESSURE
Higher average interdialytic ambulatory BP predicts mortality in hemodialysis patients [6] . In general, individual hemodialysis-unit BP measurements lack precision in estimating ambulatory BP [26] . Inclusion of multiple intradialytic BP measurements in addition to prehemodialysis and posthemodialysis measurements improves the accuracy of diagnosing hypertension as compared to prehemodialysis or posthemodialysis measurements alone [27] . Thus, it is clear that the relationship between ambulatory BP and intradialytic BP measurements is strengthened by including more than a single hemodialysis unit measurement. However, these findings do not specifically address the relationship between the intradialytic BP pattern and ambulatory BP. Because intradialytic hypertension has been associated with increased morbidity and mortality, it is important to know how increases in BP during hemodialysis relate to BP measurements during the interdialytic period. We recently reported the results of a case-control study examining the relationship between intradialytic hypertension and ambulatory BP [28 && ]. All patients in this study had prehemodialysis SBP more than 140 mmHg or posthemodialysis SBP more than 130 mmHg during a 2-week screening period. Cases (n ¼ 25) were those with SBP increases from prehemodialysis to posthemodialysis of at least 10 mmHg in at least four of six screening hemodialysis treatments, and controls were those with SBP decreases of at least 10 mmHg in at least four of six screening hemodialysis treatments [28 && ]. The average 44-h ambulatory SBP was significantly higher (155.4 vs. 142.4 mmHg) in patients with intradialytic hypertension compared with controls. This elevated BP persisted after performing individual analyses of daytime and nocturnal SBP and DBP. A 'nondipping' nocturnal BP pattern was almost universal in the study (98% of cases, 100% of controls). There were strong correlations with interdialytic BP and both prehemodialysis and posthemodialysis BP. The strongest correlation with interdialytic BP for both groups was with the average of prehemodialysis and posthemodialysis BP. In addition to the difference in average ambulatory BP, there was also a demonstrable difference in the ambulatory BP pattern. During the first 24 h after hemodialysis, SBP was higher in those with intradialytic hypertension as compared with controls, but demonstrated a decreasing trend over time. After 24 h, BP increased among patients with intradialytic hypertension until shortly before the next hemodialysis treatment. In contrast, the BP of the control group had a gradual increase from the first hour after hemodialysis until shortly before the next treatment (Fig. 2) [28 && ]. The ambulatory BP pattern in the control group is consistent with what had previously been reported in hemodialysis patients between treatments [29] . The discrepancy between the two patterns in the case-control study suggests that patients with intradialytic hypertension may be less salt-sensitive during the initial period after hemodialysis, and that other factors such as vasoconstriction may be predominantly responsible for the elevated BP during this time.
In a previous analysis of interdialytic BP in hemodialysis patients, arterial stiffness and interdialytic weight gain modified the BP pattern between treatments [30] . Specifically, greater arterial stiffness was associated with a higher intercept (posthemodialysis BP) for a given amount of weight gain. Greater interdialytic weight gain was associated with a greater slope or hourly increase in BP for a given level of arterial stiffness. Retrospective analysis of the DRIP study demonstrated that gradual reduction in dry weight results in a lower posthemodialysis BP, but an increased interdialytic BP slope [31] . However, in all of these scenarios, there Hours after hemodialysis FIGURE 2. Average hemodialysis unit prehemodialysis and posthemodialysis SBP and hourly ambulatory SBP in intradialytic hypertension patients and hemodialysis controls. On the left (a and b) are the prehemodialysis (pre-HD) and post-HD unit SBP measurements averaged over 2 weeks that were reported in a recent case-control study [28 && ]. SBP increases from predialysis to postdialysis in patients with intradialytic hypertension (a), and it decreases in HD controls (b). On the right (c and d) are plots of the ambulatory SBP during each hour of the interdialytic period. In patients with intradialytic hypertension, there is a trend toward a decrease in ambulatory blood pressure for the initial 24 h, after which the blood pressure increases until the next HD treatment (c). In the HD controls, the systolic ambulatory blood pressure increases during the entire interdialytic period (d).
remained a rather consistent increase in SBP during the 44-h interdialytic period, which did not occur among our patients with intradialytic hypertension (Fig. 2) .
Finally, the impact of specific antihypertensive medications on ambulatory BP patterns remains unclear. In our case-control cohort, more patients with intradialytic hypertension than controls were taking angiotensin-converting enzyme (ACE) inhibitors but there was no difference in overall use of ACE inhibitors or angiotensin receptor blockers between groups. All patients receiving ACE inhibitors were either on lisinopril or quinapril. Both of these medications are potentially dialyzable and may have modified both the intradialytic BP and the interdialytic BP for several hours after the treatment.
CURRENT RECOMMENDATIONS
Our data demonstrate that intradialytic hypertension is associated with an overall increased interdialytic BP burden. Although greater awareness of this subpopulation is warranted, there is insufficient evidence to indicate that deviating from the current recommendations for treating hypertension in the general hemodialysis population is necessary. As with all hemodialysis patients, identifying and achieving dry weight is essential. Dry weight reduction lowers intradialytic and interdialytic BP in most hemodialysis patients [14 && ]. However, pharmacologic antihypertensive therapy is still often necessary and has been associated with a mortality benefit in hemodialysis patients [32, 33] . Although inhibitors of the renin-angiotensinaldosterone system are considered first-line agents for hemodialysis patients, it is important to recognize differences in the dialyzability of antihypertensive drugs. Antihypertensive selection for specific comorbidities in hemodialysis patients and the dialyzability of various drugs are provided in a recent review [34] . The benefits of switching from a dialyzable antihypertensive to a nondialyzable drug remain uncertain regarding the overall effects on intra/interdialytic BP or morbidity/mortality. Early results of the Mechanisms and Treatment of Intradialytic Hypertension Study (NCT00827775) [9] suggest carvedilol to be a good therapeutic option among those with intradialytic hypertension. In this prospective open-label study of carvedilol among 25 hemodialysis patients with intradialytic hypertension, chronic oral administration of carvedilol, an antihypertensive agent that has been shown to lower endothelin-1, both improved endothelial cell function and reduced the frequency of intradialytic hypertension [35] .
FUTURE DIRECTIONS
The higher average ambulatory BP in patients with intradialytic hypertension provides a potential explanation for the increased risk for adverse events observed among these patients, but the differences in the ambulatory BP pattern remain intriguing and unexplained to date. This concept has relevance to the more generalizable hemodialysis population as well. Although the average of ambulatory BP measurements predicts mortality in hemodialysis patients, it is unknown whether prolonged periods of moderately elevated BP or intermittent periods of severely elevated BP during the interdialytic interval are associated with greater morbidity and mortality. Although limited by only 24 h of posthemodialysis ambulatory BP measurements, one cross-sectional study found no difference in left ventricular hypertrophy in patients who were hypertensive during and 24 h after hemodialysis and patients with normal posthemodialysis BP but steady increases in BP to the hypertensive level for the next 24 h [36] . Understanding the underlying mechanisms responsible for BP elevations throughout the entire interdialytic period would facilitate a more targeted approach to BP management in hemodialysis patients. In short, the method of achieving lower average ambulatory BP, the gold standard for assessing risk in hemodialysis patients, may depend on what factors are influencing the interdialytic BP at different points in time. For patients with intradialytic hypertension, the components of both extracellular volume and increased vasoconstriction from endothelial cell dysfunction should be considered. Finally, it remains unknown how differences in the hourly interdialytic BP affect outcomes in hemodialysis patients with or without intradialytic hypertension.
CONCLUSION
Intradialytic hypertension is an under-recognized marker of increased risk for morbidity and mortality among maintenance hemodialysis patients. Endothelial cell dysfunction appears to be a major mechanism underlying this phenotype, and the role of extracellular volume overload remains to be better defined. Patients with intradialytic hypertension have higher ambulatory BP than other hemodialysis patients. The differences in the ambulatory hourly BP patterns between the groups warrant a closer examination of how endothelial cell dysfunction and volume overload impact interdialytic BP patterns in all hemodialysis patients. Whether prevention or treatment of intradialytic hypertension improves outcomes in this high-risk group is an important clinical question that requires further investigation.
